Zenodo (CERN European Organization for Nuclear Research)
May 13, 2022
Liliana Irizabal
preprint
This project is a systematic review that highlights how beneficial psychedelic psychotherapy can be to those suffering with mental illness. The three mental illnesses chosen to be analyzed in the literature were depression, post-traumatic stress disorder (PTSD), and anxiety. The drugs used in the specific articles included Psilocybin, Ayahuasca(DMT), and MDMA (3,4-methylenedioxymethamphetamine;...
Translational Psychiatry
May 2, 2022
Ruin Moaddel, Panos Zanos, Cristan A Farmer et al.
32 citations
Abstract Subanesthetic-dose racemic ( R,S )-ketamine (ketamine) produces rapid, robust, and sustained antidepressant effects in major depressive disorder (MDD) and bipolar disorder (BD) and has also been shown to effectively treat neuropathic pain, complex regional pain syndrome, and post-traumatic stress disorder (PTSD). However, to date, its mechanism of action remains unclear. Preclinical...
The FASEB Journal
May 1, 2022
Suzanne Underhill, Susan Amara
The use of 3,4‐methylenedioxymethamphetamine (MDMA) has recently gained interest as a potential therapeutic tool for the treatment of post‐traumatic stress disorder (PTSD). However, the mechanism of action of this drug has not yet been fully elucidated. Here we demonstrate that MDMA acts by targeting the trace amine associated receptor 1 (TAAR1), an intracellular G‐protein coupled receptor...
European Journal of Futures Research
April 30, 2022
Claudia Schwarz-Plaschg
36 citations
Abstract After decades of criminalization, psychedelic substances such as psilocybin and LSD are experiencing their comeback in science and Western culture more broadly. While psychedelic plants and fungi have a long history of use in Indigenous cultures, the Western prohibitionist reality instantiated around 1970 has stigmatized psychedelics as medically useless and a threat to society. Yet...
Frontiers in Psychiatry
April 25, 2022
Peter Oehen, Peter Gasser
70 citations
The Swiss Federal Act on Narcotics allows for the restricted medical use of scheduled psychotropic drugs in cases of resistance to standard treatment, and preliminary evidence of efficacy of the scheduled drug for the particular condition. Since 2014, the authors have obtained 50 licenses on a case-by-case basis and developed a psychedelic-assisted group therapy model utilizing MDMA and LSD....
Journal of Trauma & Dissociation
April 15, 2022
D. Simeon, Frank W. Putnam
ABSTRACT Our aim was to examine U.S. national prevalence of pathological dissociation (PD) likely indicative of dissociative disorder, and associated morbidity, comorbidity, and childhood maltreatment. PD was assessed in 6,644 participants in the National Comorbidity Survey Replication, a nationally representative adult survey. Seven of the eight pathological dissociation taxon items were...
Discover Mental Health
April 15, 2022
Mani Yavi, Holim Lee, Ioline D. Henter et al.
150 citations
-enantiomer, intranasal esketamine, for the treatment of major depressive disorder (MDD). Initial studies found that a single subanesthetic-dose IV ketamine infusion rapidly (within one day) improved depressive symptoms in individuals with MDD and bipolar depression, with antidepressant effects lasting three to seven days. In 2019, esketamine received FDA approval as an adjunctive treatment for...
BJPsych Open
April 11, 2022
E. Vissia, A. Lawrence, S. Chalavi et al.
Background Memory function is at the core of the psychopathology of dissociative identity disorder (DID), but little is known about its psychobiological correlates. Aims This study aims to investigate whether memory function in DID differs between dissociative identity states Method Behavioural data and neural activation patterns were assessed in 92 sessions during an n-back working memory...
Journal of Clinical Sleep Medicine
April 11, 2022
Rachel M. Ranney, R. Gloria, Thomas J. Metzler et al.
Trauma-related nightmares are highly prevalent among veterans and are associated with higher-severity insomnia and posttraumatic stress disorder. Cognitive behavioral therapy for insomnia (typically 6–8 sessions) has been shown to reduce trauma-related nightmares. Brief behavioral treatment for insomnia (BBTI, 4 sessions) has been found to be comparable to CBT-I in decreasing insomnia severity;...
Expert Opinion on Drug Safety
April 6, 2022
M. I. Husain, M. Umer, Benoit H. Mulsant
Classic psychedelics are a loosely grouped class of drugs that activate serotonin 5HT2A receptors to induce complex behavioral, psychological, and physiological effects [1]; 5HT2A agonism induces the hallucinogenic experiences that distinguish psychedelics [2] while pre-medicating with a 5HT2A antagonist, such as ketanserin, prevents them [3,4]. In the 1950s and 1960s, after Albert Hoffman’s...